Pastorello E A, Ortolani C, Gerosa S, Pravettoni V, Codecasa L R, Fugazza A, Zanussi C
School of Allergy and Clinical Immunology, 2nd Department of Internal Medicine, University of Milan, Italy.
Pharmatherapeutica. 1987;5(2):69-75.
A double-blind study was carried out in 65 patients with seasonal rhinitis to compare the effectiveness and tolerance of terfenadine and dexchlorpheniramine. Patients were allocated at random to receive treatment for 1 week with either 60 mg terfenadine twice daily or 2 mg dexchlorpheniramine maleate 3-times daily. Before and after treatment, patients underwent RAST and skin prick tests for reactivity to pollen and those who were positive also had rhinomanometric measurements made of nasal resistance. Diary cards were used by patients to record the severity of nasal obstruction, rhinorrhoea, sneezing, watery, irritated and red eyes, itching of the nose, throat and eyes, and cough. Details were also kept of the frequency and severity of any side-effects. Pollen counts were taken daily during the treatment period. The results showed that both terfenadine and dexchlorpheniramine produced good or excellent relief of the main symptoms in 78% and 73% of the patients, respectively. There was no significant correlation between the pollen count and reduced symptom severity. Both drugs produced a reduction in total nasal resistance but this was not significantly different from initial values, neither was there a significant difference between treatment. Terfenadine was well tolerated and side-effects incidence was significantly lower (p less than 0.01) than in patients treated with dexchlorpheniramine, particularly so with reference to drowsiness.
对65例季节性鼻炎患者进行了一项双盲研究,以比较特非那定和右氯苯那敏的疗效及耐受性。患者被随机分配,分别接受为期1周的治疗,其中一组每日两次服用60毫克特非那定,另一组每日三次服用2毫克马来酸右氯苯那敏。治疗前后,患者接受了放射性变应原吸附试验(RAST)和皮肤点刺试验,以检测对花粉的反应性,对阳性患者还进行了鼻阻力的鼻测压测量。患者使用日记卡记录鼻塞、流涕、打喷嚏、眼睛水汪汪、受刺激和发红、鼻痒、喉痒、眼痒以及咳嗽的严重程度。还详细记录了任何副作用的发生频率和严重程度。在治疗期间每天记录花粉计数。结果显示,特非那定和右氯苯那敏分别使78%和73%的患者的主要症状得到良好或极佳缓解。花粉计数与症状严重程度减轻之间无显著相关性。两种药物均使总鼻阻力降低,但与初始值相比无显著差异,两种治疗之间也无显著差异。特非那定耐受性良好,副作用发生率显著低于(p<0.01)接受右氯苯那敏治疗的患者,尤其是嗜睡方面。